Gaignage, Mélanie
Zhang, Xuhao
Stockis, Julie
Dedobbeleer, Olivier
Michiels, Camille
Cochez, Perrine
Dumoutier, Laure
Coulie, Pierre G.
Lucas, Sophie http://orcid.org/0000-0003-1287-7996
Funding for this research was provided by:
Fondation Contre le Cancer (F/2016/837)
European Research Council (TARG-SUP 682818)
ARC Actions de Recherche Concertees (14/19-056)
Fonds De La Recherche Scientifique - FNRS (T.0089.16)
WALinnov, IMMUCAN (1610119)
WELBIO Walloon Excellence in Life Sciences and Biotechnology (CR-2019A-02)
China Scholarship Council
Article History
Received: 19 April 2021
Accepted: 22 November 2021
First Online: 1 January 2022
Declarations
:
: Patents pertaining to blocking antibodies against human GARP:TGF-b1 have been filed under the Patent Cooperation Treaty (International application Number PCT/IB2019/053753), with Sophie Lucas, Pierre G. Coulie, and Laure Dumoutier as inventors and UCLouvain as applicant. The anti-mouse GARP:TGF-b1 antibody (clone 58A2) used herein is a surrogate for these antibodies. All other authors declare no competing interests.
: All mice were bred at the SPF animal facility of the UCLouvain. <i>C. rodentium</i> infection and immunization studies were performed in accordance with national and institutional guidelines for animal care, under permit number 2017/UCL/MD/019 from the UCLouvain.